Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

People who took semaglutide over a slower, more flexible schedule were significantly less likely to experience nausea and to ...

If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long ...

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Wegovy® is indicated for chronic weight management in adults and adolescents (12+) with obesity or overweight and at least one related health condition. The once-weekly injectable supports weight loss ...

Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

SINGAPORE - Media OutReach Newswire - 12 July 2025 - A significant advancement in weight management has arrived for Singaporeans. Novo Nordisk, a global healthcare company focused on defeating serious ...

The market for generic GLP-1 weight loss drugs in Canada is set to open up, and Hims & Hers is ready to jump in.  | Novo ...